 |
| 13-Jun-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$45 → $48 |
|
| 05-Jun-13 | Upgrade |
Argus |
Hold → Buy |
$46 |
|
| 18-Apr-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$48 → $45 |
|
| 16-Jan-13 | Reiterated |
Deutsche Bank |
Hold |
$34 → $36 |
|
| 09-Nov-12 | Initiated |
Mizuho |
Buy |
$45 |
|
| 26-Apr-12 | Initiated |
Auriga |
Hold |
$36 |
|
| 18-Apr-12 | Reiterated |
Cantor Fitzgerald |
Buy |
$41 → $45 |
|
| 09-Dec-11 | Initiated |
Barclays Capital |
Equal Weight |
$30 |
|
| 25-Oct-11 | Downgrade |
Argus |
Buy → Hold |
|
|
| 19-Oct-11 | Reiterated |
UBS |
Neutral |
$34 → $32 |
|
| 15-Sep-11 | Reiterated |
UBS |
Neutral |
$40 → $34 |
|
| 22-Jun-11 | Upgrade |
Argus |
Hold → Buy |
$46 |
|
| 20-Oct-10 | Reiterated |
UBS |
Neutral |
$34.32 |
|
| 14-Sep-10 | Reiterated |
UBS |
Neutral |
$29 → $32 |
|
| 14-Sep-10 | Reiterated |
Deutsche Bank |
Hold |
$29 → $33 |
|
| 09-Jun-10 | Initiated |
Caris & Company |
Buy |
$36 |
|
| 21-Apr-10 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 08-Apr-10 | Downgrade |
Piper Jaffray |
Neutral → Underweight |
$27 → $26 |
|
| 05-Jan-10 | Reiterated |
Wedbush Morgan |
Neutral |
$32 → $35 |
|
| 18-Dec-09 | Initiated |
Soleil |
Buy |
$38 |
|
|
|
| 20-Jun-13 08:20AM | Stock futures fall in wake of Fed's stimulus wind-down outline Reuters |
| 08:17AM | US STOCKS-Futures fall in wake of Fed's stimulus wind-down outline at Reuters |
| 08:03AM | Early Movers: RAD, HPQ, MU, FDX, WMT & More at CNBC |
| 07:48AM | Stock futures drop in wake of Fed's stimulus-tapering outline Reuters |
| 07:45AM | US STOCKS-Futures drop in wake of Fed's stimulus-tapering outline at Reuters |
| 19-Jun-13 04:30PM | Exclusive: Forest mulls bid for Irish drugmaker Elan - sources Reuters |
| 03:34PM | Forest Laboratories one of several suitors for Elan, report says at MarketWatch |
| 03:00PM | Exclusive - Forest keen to bid for Irish drugmaker Elan - sources Reuters |
| 02:35PM | Exclusive: Forest keen to bid for Irish drugmaker Elan - sources Reuters |
| 02:19PM | Forest Rises On Unusually High Volume (FRX) at TheStreet |
| 02:01PM | Exclusive: Forest interested in bidding for Irish drugmaker Elan - sources at Reuters |
| 02:01PM | Exclusive: Forest interested in bidding for Irish drugmaker Elan - sources Reuters |
| 08:46AM | Eli Lilly: Cymbalta Antidepressant Sales Forecast at Seeking Alpha |
| 18-Jun-13 06:01PM | Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel at Bloomberg |
| 04:47PM | 5 High Growth Healthcare Stocks With Heavy Insider Buying at TheStreet |
| 17-Jun-13 05:00PM | US Launch of Forest's Namenda XR Zacks |
| 03:22PM | Synergy Pharma rises as analyst starts coverage AP |
| 02:37PM | Can Cempra Beat The Superbugs? at Seeking Alpha |
| 10:00AM | Forest Reaches New 52-Week High (FRX) at TheStreet |
| 14-Jun-13 05:00PM | Forest Laboratories Inc. (FRX): Today's Featured Health Care Winner at TheStreet |
| 13-Jun-13 02:10PM | Analysts: BlackBerry Sales Tracking Over Estimates and 3 More Research Notes to Investigate at Wall St. Cheat Sheet |
| 08:01AM | InPlay: Forest Labs announces U.S. availability of new once-daily NAMENDA XR Briefing.com |
| 08:00AM | Forest Announces U.S. Availability of New Once-Daily NAMENDA XR Business Wire |
| 06:01AM | Some Dividend Stocks May Still Look Like Winners at Seeking Alpha |
| 12-Jun-13 05:13PM | Analysts: Tesla Should Hit Its Gen III Targets and 3 More Research Notes to Look Over at Wall St. Cheat Sheet |
| 09:04AM | Today's Market: No One Wants To Be The Evil Empire at Seeking Alpha |
| 11-Jun-13 06:31PM | 4 Healthcare Stock Stories For Thursday Inspection at Wall St. Cheat Sheet |
| 05:30PM | Forest Laboratories Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 11:20 AM at Seeking Alpha |
| 04:08PM | InPlay: Forest Labs: Carl Icahn discloses 11.50% active stake (~30.7 mln shares) in amended 13D filing; entered into a Nomination and Standstill Agreement and a Confidentiality Agreement Briefing.com |
| 04:04PM | Forest Adds Icahn Director in Pact to Avoid Proxy Fight at Bloomberg |
| 02:44PM | Forest Labs to add Icahn rep to board, avert proxy fight Reuters |
| 01:04PM | 5 Drugs Stocks Dragging The Industry Down at TheStreet |
| 12:10PM | Forest Labs Appoints Icahn Board Member, Avoids Proxy Fight at Barrons.com |
| 11:12AM | Forest Labs to add Icahn representative to board, avert proxy fight Reuters |
| 11:10AM | Forest Labs to add Icahn rep to board, avert proxy fight at Reuters |
| 11:05AM | [$$] Forest Labs Names New Board Member in Deal with Icahn at The Wall Street Journal |
| 09:17AM | Forest Laboratories names Icahn designee to board AP |
| 08:49AM | Forest Adds Icahn Director in Pact to Avoid Proxy Fight at Bloomberg |
| 08:07AM | InPlay: Forest Labs appoints new independent Director Briefing.com |
| 08:00AM | Forest Laboratories Appoints New Independent Director Business Wire |
| 01:09AM | FOREST LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib EDGAR Online |
| 10-Jun-13 01:00PM | AstraZeneca Pays Up To Patch Up Another Key Area at Investopedia |
| 11:33AM | AstraZeneca Buying Pearl As COPD Drug Race Heats Up at Investor's Business Daily |
| 10:05AM | AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion Reuters |
| 07:45AM | Sanofi MS drug nears green light after pass-the-parcel marathon at Reuters |
| 06:24AM | AstraZeneca buys U.S. lung drug firm Pearl for up to $1.15 billion Reuters |
| 07-Jun-13 06:49PM | 4 Healthcare Stock Stories As a Weekend Investment Prescription at Wall St. Cheat Sheet |
| 11:31AM | Pepsi Turns Eyes to China, Syntas Insider Trades and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 10:35AM | Forest Stock Hits New 52-Week High (FRX) at TheStreet |
| 08:30AM | Today's Market: Government News To Move The Markets at Seeking Alpha |
| 06:32AM | Exclusive: Forest braces for third bout with Icahn Reuters |
| 06-Jun-13 08:11AM | Bristol-Myers Squibb: The Untold Story Of Led Zeppelin at Seeking Alpha |
| 05-Jun-13 01:17AM | Forest Labs upgraded by Argus Briefing.com |
| 04-Jun-13 08:32AM | The Dope On A Forest Labs Takeover at Seeking Alpha |
| 07:22AM | Bermuda With Ireland Targets of Tax Vigilantes, Minister Says at Bloomberg |
| 01-Jun-13 09:02PM | This Drugmaker Should Go Fishing for a Marketing Partner at Motley Fool |
| 31-May-13 04:48PM | Forest Bulks Up Its Cardiovascular Franchise at Motley Fool |
| 01:05PM | FOREST LABORATORIES INC Financials EDGAR Online Financials |
| 10:11AM | Apple No Ghost in Ireland Where Cork Frets Senate Hearing at Bloomberg |
| 04:58AM | Apple No Ghost in Ireland Where Cork Frets Senate Hearing: Taxes at Bloomberg |
| 30-May-13 01:42PM | Ironwood Pharma rises following analyst upgrade AP |
| 29-May-13 12:38PM | [video] Ratings Moves: LMT, FRX, ORI at TheStreet |
| 10:05AM | Forest Laboratories Inc. Stock Upgraded (FRX) at TheStreet |
| 28-May-13 10:19AM | Forest Reaches New 52-Week High (FRX) at TheStreet |
| 09:40AM | Valeant Eyes Bausch & Lomb at Investopedia |
| 27-May-13 08:00AM | 2 Biotech Stocks in Activist Investors' Crosshairs at Motley Fool |
| 25-May-13 10:10AM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 24-May-13 02:15PM | DOJ subpoenas documents on Forest Labs' inhalation drug Reuters |
| 02:10PM | U.S. DOJ subpoenas documents on Forest Labs' inhalation drug at Reuters |
| 01:18PM | NYSE stocks posting largest percentage increases AP |
| 11:05AM | Positive Data from Synergy Pharma Zacks |
| 05:52AM | FOREST LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online |
| 05:45AM | Apples Tax Magic Leaves Irish Bondholders Unmoved: Euro Credit at Bloomberg |
| 23-May-13 09:52PM | Forest Labs CEO to Retire at Motley Fool +5.39% |
| 07:01PM | Apples Tax Magic Leaves Irish Bondholders Unmoved: Euro Credit at Bloomberg |
| 06:49PM | 4 Healthcare Stock Stories Prescribed For Investors at Wall St. Cheat Sheet |
| 06:05PM | NYSE stocks posting largest percentage increases AP |
| 05:15PM | Today's 3 Best Stocks at Motley Fool |
| 03:59PM | Forest Labs climbs as CEO announces retirement AP |
| 03:54PM | [$$] Forest Laboratories CEO to Retire at The Wall Street Journal |
| 03:09PM | [$$] Forest Laboratories CEO Solomon to Retire Dec. 31 at The Wall Street Journal |
| 03:01PM | Forest Rises On Unusually High Volume (FRX) at TheStreet |
| 11:52AM | Forest Labs' longtime CEO Solomon to step down at year-end Reuters |
| 11:35AM | Ironwood Pharma Prices Stock Offering Zacks |
| 10:34AM | Forest Labs CEO Howard Solomon to retire AP |
| 10:29AM | FOREST LABORATORIES INC Files SEC form 10-K, Annual Report EDGAR Online |
| 09:43AM | Oakmark Fund Buys Forest Laboratories, DirecTV, UnitedHealth, Apple at Forbes |
| 09:40AM | Forest Labs' longtime CEO Solomon to step down at year-end at Reuters |
| 08:09AM | Forest Laboratories Says Solomon to Leave CEO Post at Bloomberg |
| 08:04AM | InPlay: Forest Labs provides update on succession planning; Howard Solomon to retire as CEO and President at end of 2013; will serve as chairman to 2014 AGM and then become Chairman Emeritus Briefing.com |
| 08:00AM | Forest Laboratories Provides Update on Succession Planning Business Wire |
| 22-May-13 06:04PM | Will Ranbaxy Labs Be Excluded From Medicare And Medicaid? at Forbes |
| 01:08PM | Did Apple Pare Its Tax Bill With a 'Double Irish?' at BusinessWeek |
| 07:35AM | Apple Got No Sweetheart Accord on Corporate Tax Bill, Irish Say at Bloomberg |
| 12:15AM | Google Joins Apple Avoiding Taxes With Stateless Income at Bloomberg |
| 21-May-13 01:41PM | Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide at Seeking Alpha |
| 09:27AM | Is There a Pill For That? Forest Labs Iffy Pipeline YCharts |
| 20-May-13 05:01PM | Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg |
| 01:56PM | July Options Now Available For Forest Laboratories (FRX) at TheStreet |
| 17-May-13 08:08AM | Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference Business Wire |
|
|
| Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. It principally offers Namenda for the treatment of moderate and severe Alzheimer's disease; Bystolic for the treatment of hypertension; Savella for the management of fibromyalgia; Teflaro for the treatment of adults with skin and skin structure infections, and community-acquired bacterial pneumonia; Daliresp to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD; and Viibryd for the treatment of adults with major depressive disorder (MDD). The company has products under new drug application review by Food and Drug Administration comprising Aclidinium for the maintenance treatment of COPD; and Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation. It also develops ceftaroline/avibactam combination, which is under Phase III clinical trials for complicated intra-abdominal infections, as well as has completed Phase II clinical trials for complicated urinary tract infections; and Cariprazine that is in Phase III clinical trials for the treatment of acute exacerbation of schizophrenia and acute mania associated with bipolar disorder. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; GRT 6005 that is under Phase II clinical trials for nociceptive and neuropathic pain; TTP399, which is under Phase II clinical trials for the treatment of Type II diabetes; and RGH-618 that is under Phase I clinical trials for the treatment of anxiety, depression, and other central nervous system conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. The company was founded in 1956 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Basgoz Nesli | Director | Mar 07 | Option Exercise | 27.40 | 9,621 | 263,633 | 18,695 | Mar 11 02:59 PM | | Basgoz Nesli | Director | Mar 07 | Sale | 37.46 | 12,200 | 456,954 | 6,495 | Mar 11 02:59 PM | | OLANOFF LAWRENCE S | Director | Mar 04 | Sale | 36.77 | 543 | 19,968 | 90,697 | Mar 04 03:20 PM | | Meury William | SVP - Marketing | Feb 06 | Option Exercise | 26.65 | 26,350 | 702,243 | 108,266 | Feb 08 09:30 AM | | Meury William | SVP - Marketing | Feb 06 | Sale | 35.73 | 26,350 | 941,603 | 81,916 | Feb 08 09:30 AM | | Weinstein Herschel S | SVP General Counsel | Jan 18 | Sale | 36.57 | 7,000 | 255,961 | 87,885 | Jan 23 10:09 AM | | Francis Perier I Jr | EVP Finance & Admin. & CFO | Dec 10 | Sale | 36.52 | 15,942 | 582,125 | 94,665 | Dec 12 11:26 AM | | Taglietti Marco | Sr.VP-R&D & Chief Medical Off. | Sep 06 | Sale | 35.51 | 13,000 | 461,631 | 107,568 | Sep 10 01:42 PM | | ICAHN CARL C | 10% Owner | Sep 05 | Buy | 34.65 | 561 | 19,439 | 30,286,349 | Sep 07 05:39 PM | | OLANOFF LAWRENCE S | Director | Sep 05 | Sale | 34.90 | 561 | 19,581 | 91,240 | Sep 06 01:12 PM | | ICAHN CARL C | 10% Owner | Sep 04 | Buy | 34.65 | 16,859 | 584,164 | 30,285,788 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 31 | Buy | 34.65 | 6,274 | 217,394 | 30,268,929 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 30 | Buy | 34.63 | 63,715 | 2,206,450 | 30,262,655 | Sep 04 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 29 | Buy | 34.65 | 130,728 | 4,529,725 | 30,198,940 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 28 | Buy | 34.64 | 4,052 | 140,361 | 30,068,212 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 27 | Buy | 34.65 | 196,626 | 6,813,091 | 30,064,160 | Aug 29 05:32 PM | | ICAHN CARL C | 10% Owner | Aug 24 | Buy | 34.64 | 152,442 | 5,280,591 | 29,867,534 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 23 | Buy | 34.59 | 562,777 | 19,466,456 | 29,715,092 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 22 | Buy | 34.53 | 628,618 | 21,706,180 | 29,152,315 | Aug 24 05:14 PM | | ICAHN CARL C | 10% Owner | Aug 21 | Buy | 34.35 | 732,460 | 25,160,001 | 28,523,697 | Aug 21 05:26 PM | | ICAHN CARL C | 10% Owner | Aug 20 | Buy | 34.14 | 371,551 | 12,684,751 | 27,791,237 | Aug 21 05:26 PM | | ICAHN CARL C | 10% Owner | Aug 17 | Buy | 34.05 | 858,000 | 29,212,900 | 27,419,686 | Aug 21 05:26 PM | | Lynch Jerome | SVP-Sales | Aug 03 | Sale | 32.77 | 1,500 | 49,149 | 69,300 | Dec 07 03:55 PM |
|
|
|
|
|
|
